瘤性2的可溶性抑制与冠状动脉疾病的风险和严重程度之间的关联:一个病例对照研究

Shuai Zhang1, Lu Qian2, Shibao Li1

  • 1Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, No.99 Huaihai West Road, Xuzhou, 221002, Jiangsu, China.

PubMed
概括

在冠状动脉疾病 (CAD) 患者中,可溶性抑制瘤发生率2 (sST2) 水平升高,与动脉样硬化严重程度相关. sST2显示出作为CAD诊断,进展和风险分层的生物标志物的潜力.